Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Working Capital Changes: 2021-2025

Historic Other Working Capital Changes for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$129,992.

  • InMed Pharmaceuticals' Other Working Capital Changes rose 60.47% to -$129,992 in Q3 2025 from the same period last year, while for Sep 2025 it was -$231,005, marking a year-over-year increase of 47.89%. This contributed to the annual value of -$429,880 for FY2025, which is 8.17% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Other Working Capital Changes stood at -$129,992, which was down 13.37% from -$114,659 recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Other Working Capital Changes high stood at $1.2 million for Q1 2022, and its period low was -$918,075 during Q2 2024.
  • Its 3-year average for Other Working Capital Changes is -$128,507, with a median of -$114,659 in 2025.
  • In the last 5 years, InMed Pharmaceuticals' Other Working Capital Changes skyrocketed by 320.82% in 2022 and then tumbled by 741.61% in 2024.
  • InMed Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at -$212,964 in 2021, then soared by 320.82% to $470,266 in 2022, then skyrocketed by 90.95% to $897,962 in 2023, then plummeted by 86.09% to $124,943 in 2024, then soared by 60.47% to -$129,992 in 2025.
  • Its Other Working Capital Changes stands at -$129,992 for Q3 2025, versus -$114,659 for Q2 2025 and -$111,297 for Q1 2025.